Whilst AFP has been commonly used as a serum biomarker of tumour response for HCC for many years, one of its major limitations is that approximately 30–50% of patients with HCC are AFP non-secretors [28, 29]. This evidence concerns the gene AFP and hepatocellular carcinoma.